Can a drug block inflammation and lower lung cancer risk in Ex-Smokers?
NCT ID NCT06038526
First seen Jan 07, 2026 · Last updated Apr 28, 2026 · Updated 13 times
Summary
This study looks at how canakinumab, a drug that reduces inflammation, affects cells in the mouth, nose, and blood of former smokers who are at high risk for lung cancer. The goal is to see if blocking a specific inflammatory protein can slow or prevent cancer growth. About 41 participants will provide samples before and after treatment to measure changes in key markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.